NCT05690035View on ClinicalTrials.gov

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Metastatic Colorectal CancermCRC
Interventions
DRUG

Tislelizumab & Fruquintinib

combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent

Trial Locations (2)

510060

Sun Yat-sen University, Cancer Center, Guangzhou

Unknown

Xiaoshi Zhang, Guangzhou

Sponsors

Collaborators (2)

Hutchmed
BeiGene
All Listed Sponsors
collaborator

Hutchmed

INDUSTRY

collaborator

BeiGene

INDUSTRY

lead

Sun Yat-sen University

OTHER